Testing a new inhaled medication for lung blood pressure in healthy adults

Plain-English translation of NCT06429930 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new inhaled medication called L608, which is a special formulation of a drug called iloprost designed to treat pulmonary arterial hypertension (a condition where blood pressure in the lungs becomes dangerously high). This Phase 1 study is enrolling healthy adults to find out if the medication is safe and how the body processes it, before it can be tested in patients who actually have the disease.

The current treatment for pulmonary arterial hypertension requires frequent dosing and can cause unwanted side effects like low blood pressure. This new formulation is designed to reduce how often patients need to take the medication and minimize those troubling side effects.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have a healthy weight (BMI between 18.5 and 32.0) and weigh at least 110 pounds
you are a non-smoker or have smoked very little (no more than 100 cigarettes total in your life) and have not used any tobacco for at least 3 months
if you are a woman, you are not pregnant or breastfeeding and agree to use effective birth control during the study and for 3 months after

You likely don't qualify if…

you have any history of unusual bleeding, coughing up blood, or blood clotting disorders
you have or have had lung diseases like asthma, sleep apnea, COPD, pulmonary fibrosis, or chronic bronchitis
you have a history of heart attack, stroke, heart disease, or serious heart rhythm problems
you have uncontrolled blood pressure (below 90 or above 140 systolic, or below 50 or above 95 diastolic)
you have used illegal drugs or alcohol heavily in the past year, or you cannot avoid alcohol for 48 hours before and during the study

What participation looks like

If you qualify, you will be randomly assigned to receive either the new medication or a placebo (a fake treatment) through inhalation. You will be one of about 32 healthy volunteers in the study, with most visits happening in New Zealand. The study uses a step-by-step approach, gradually testing higher doses to watch for safety. You will need to avoid caffeine, certain foods, alcohol, and strenuous exercise at specific times, and attend visits where researchers will check your vital signs, lung function, and blood levels.

AI-generated summary from trial data · Jun 19, 2026 · Not medical advice

Trial locations(1 site)

New Zealand

NZCR Ltd (New Zealand Clinical Research), Christchurch

Testing a new inhaled medication for lung blood pressure in healthy adults

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)

Contact the research team directly

Interested in joining?